Effects of Vitamin D Supplementation During a Non-surgical Treatment of Generalized Chronic Periodontitis

Vitamin D Deficiency Clinical Trial

— Protocol01  

Official title:

Effects of Vitamin D Supplementation During a Non-surgical Treatment of Generalized Chronic Periodontitis: A Randomized Double-blinded Placebo Controlled Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03162406
• Other study ID #: 2017/06JAN/013
• Status: Recruiting
• Phase: N/A
• First received: May 19, 2017
• Last updated: May 22, 2017
• Start date: May 18, 2017
• Est. completion date: June 30, 2018

Study information

• Verified date: May 2017
• Source: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
• Contact: Jérôme Lasserre, PhD
• Phone: 00322764
• Email: jerome.lasserre[@]uclouvain.be
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The subjects participating in the trial will be randomly allocated to either the group receiving the treatment under investigation (scaling and root planning (SRP) accompanied by administration of vitamin D) or to a group receiving standard treatment (SRP in conjunction with placebo) as the control. Random assignment of intervention will be done after subjects have been assessed for eligibility and recruited, but before the intervention to be studied begins. After randomization, the two groups of subjects will be followed in exactly the same way and the only differences between them will be the vitamin D/placebo that they will receive.

Description:

It is likely that a chronically low intake of vitamin D and calcium may lead to a negative calcium balance, thus causing a secondary increase in calcium removal from bone, including the alveolar bone. Such bone loss may contribute to weakening of the tooth-attachment apparatus. In addition to its action on skeletal homeostasis, vitamin D, and, in particular, its hormonally active form, 1a,25-dihydroxyvitamin D, has anti-inflammatory and antimicrobial effects via modulation of inflammatory cytokine production by immune cells and stimulated secretion of peptides with antibacterial action by cells of the monocyte-macrophage lineage.These multiple actions of vitamin D are potentially appealing for the management of patients with periodontal disease, whose pathogenesis is based on chronic bacterial-driven inflammation.

Excess of vitamin D leads to a disturbance of the calcium in the body cycle. The symptoms experienced are: weakness, fatigue, headache, nausea, vomiting, diarrhea, polyuria, calciuria, dry mouth, nighttime urination, proteinuria, increased thirst, loss ofappetite, dizziness.

In case of high blood calcium level for a prolonged period, calcium deposits (tissue calcinosis) may occur in the soft tissues, including the kidneys where they cause calculations and calcium deposits in the nephrons, blood vessels, heart, lung and skin. These effects are reversible if the intoxication is detected in time.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: June 30, 2018
• Est. primary completion date: June 30, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years and older

Eligibility

Inclusion Criteria:

• All subjects who are in good general health and were diagnosed with GChP (generalized chronic periodontitis) based on the current classification of the AmericanAcademy of Periodontology will be included:

• = 30 years of age,

• at least 15 teeth (excluding third molars and teeth with advanced decay indicated for extraction),

• a minimum of 6 teeth with at least one site each with periodontal probing depth (PPD) and clinical attachment level (CAL) = 5 mm,

• at least 30% of the sites with PPD and CAL = 4 mm and bleeding on probing (BOP);

• Caucasians (defined as European and North African);

• subjects who present a 25(OH)D concentration < 30 ng/mL.

Exclusion Criteria:

• pregnancy

• breastfeeding

• current smoking and former smoking within the past 5 years-smoking status will be recorded as smoker (current) or non-smoker (never or former);

• systemic diseases that could affect the progression of periodontitis (e.g. diabetes, immunological disorders, osteoporosis);

• SRP in the previous 12 months;

• antibiotic therapy in the previous 6 months;

• long-term intake of anti-inflammatory medications;

• need for antibiotic pre-medication for routine dental therapy;

• any current ongoing immunological, neoplasia, endocrine, haematological, hepatic, renal, gastrointestinal, neurological, or psychiatric abnormalities or medical disease;

• subjects who used a UV light solarium or any type of vitamin D supplement within two months before the screening visit or planned to travel outside European countries during the study

• subjets under treatment with drugs that may interfere with vitamin D metabolism (e.g., phenobarbital, phenytoin, and glucocorticoids) and those with past or current history of granulomatosis, especially sarcoidosis, urinary lithiasis, and osteomalacia;

• subjects who present a 25(OH)D concentration > 30 ng/mL, serum creatinine >150 mmol/L and and albumin corrected serum calcium >2.65 mmol/L (corresponding to 10.6 mg/dL) at screening,

• any sensitivity or allergy to any of the products that will be used in the study or a history of drug and/or alcohol abuse.

Related Conditions & MeSH terms

• Chronic Periodontitis
• Generalized Chronic Periodontitis
• Periodontitis
• Vitamin D Deficiency

Intervention

Dietary Supplement:
• Vitamin D3
Oral supplementation 25000 IU once per week for 6 months
• Placebo
Oral supplementation once per week for 6 months

Locations

Country	Name	City	State
Belgium	Cliniques universitaires Saint-Luc	Brussels

Sponsors (1)

Lead Sponsor	Collaborator
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of subjects reaching = 4 periodontal sites with PPD = 5 mm		up to 6 months
Secondary	Number of sites with PPD = 5 mm		up to 6 months
Secondary	Number of sites with PPD = 6 mm		up to 6 months
Secondary	Number of sites with PPD = 7 mm		up to 6 months
Secondary	Reduction in the number of sites with PPD = 5 mm		up to 6 months
Secondary	Reduction in the number of sites with PPD = 6 mm		up to 6 months
Secondary	Reduction in the number of sites with PPD = 7 mm		up to 6 months
Secondary	Full-mouth PPD		up to 6 months
Secondary	Full-mouth CAL		up to 6 months
Secondary	Percentage of sites with BOP		up to 6 months
Secondary	Percentage of sites with plaque accumulation		up to 6 months
Secondary	Serum vitamin D concentration		1 month before treatment and up to 6 months
Secondary	Serum high-sensitivity C-reactive Protein (hs-CRP)		1 month before treatment, at baseline, at 6 months
Secondary	Serum high-density lipoprotein (HDL) cholesterol		1 month before treatment, at baseline, at 6 months